[1] 国家卫生健康委办公厅. 临床用血技术规范:2025年版[S].北京:国家卫生健康委办公厅,2025. [2] Estcourt L J,Birchall J,Allard S,et al.Guidelines for the use of platelet transfusions[J]. Br J Haematol,2017, 176(3):365-394. [3] 庄金木,周世乔. ABO血型不相合血小板输注的临床效果与安全性研究[J]. 临床输血与检验,2024,26(4):516-521. [4] Solves Alcaina P.Platelet transfusion: and update on challenges and outcomes[J]. J Blood Med,2020,11:19-26. [5] 阳雪新,魏亚明. ABO非同型血小板输注的现状及建议[J]. 临床输血与检验,2024,26(1):17-22. [6] 阳雪新,苑召虎,陈小洁,等. 循环免疫复合物对血液病患者血小板输注疗效的影响[J]. 中国输血杂志,2022,35(4): 404-408. [7] Han M H,Badami K G.ABO non-identical platelet transfusions,immune platelet refractoriness and platelet support[J]. Br J Haematol,2024,204(5):2097-2102. [8] Magid-Bernstein J,Beaman C B,Carvalho-Poyraz F,et al.Impacts of ABO-incompatible platelet transfusions on platelet recovery and outcomes after intracerebral hemorrhage[J]. Blood,2021,137(19):2699-2703. [9] 张辰璇,许杰,王文,等. ABO次侧相容性血小板输注对异基因造血干细胞移植患者输注疗效的影响[J]. 中国实验血液学杂志,2026,34(4):1106-1113. [10] 张利,彭涛,甘新宇,等. 一种通用型组合血小板在血液病患者紧急输血中的应用与思考[J]. 中国输血杂志,2022, 35(11):1131-1135. [11] 刘忠. 全血和成分血使用标准释义[M]. 北京:人民卫生出版社,2019. [12] Association for the Advancement of Blood,Biotherapies. Technical Manual[M]. 21 st ed. Bethesda:AABB Press, 2023. [13] 中华人民共和国卫生部,中国国家标准化管理委员会. 全血及成分血质量要求: GB 18469-2012[S]. 北京:中国标准出版社, 2012. [14] Zhang Y F,Wang Y,Ma R Z,et al.Impact of platelet transfusion refractoriness in the first 30 days post-hematopoietic stem cell transplantation on outcomes of patients with myelodysplastic syndrome[J]. Front Immunol,2024,15:1437176. [15] Solves P,Sanz J,Freiria C,et al.Factors influencing platelet transfusion refractoriness in patients undergoing allogeneic hematopoietic stem cell transplantation[J]. Ann Hematol,2018,97(1):161-167. [16] Gao M Y,Huang J B,Shao Y Q,et al.Efficacy of anti-thymocyte globulin for platelet transfusion refractoriness in serious aplastic anemia patients[J]. Transfus Apher Sci,2022,61(3):103376. [17] 中华人民共和国国家卫生健康委员会. 儿科输血指南: WS/T 795-2022[S].2022. [18] Aster R H.Blood platelet kinetics and platelet transfusion[J]. J Clin Invest,2013,123(11):4564-4565. [19] 尚倩文,谭斌,彭卓越,等. 血液病患者血小板抗体检测及血小板输注疗效评估[J]. 中国输血杂志,2022,35(10): 1023-1027. [20] Andreu G,Boudjedir K,Meyer N,et al.Platelet additive solutions and pathogen reduction impact on transfusion safety,patient management and platelet supply[J]. Transfus Med Rev,2025,39(1):150875. [21] Spelmink S E,Jager S T,van de Watering L,et al. Efficacy and safety of platelet additive solution-E stored platelet concentrates[J]. Transfusion,2023,63(12):2273-2280. [22] Chen Q F,Li P,Xie Y.Comparing efficacy of apheresis and whole-blood derived platelets transfusions in acute leukemia patients who undergo chemotherapy without remission[J]. Blood,2009,114(22):4189. [23] Chen L F,Pan J C,Feng Q,et al.Analysis of factors influencing posttransfusion effectiveness in 26045 cases of platelet transfusion[J]. Zhongguo Shi Yan Xue Ye Xue Za Zhi,2015,23(4):1081-1086. [24] Sun X Y,Cai Y F,Ni H,et al.Therapeutic efficacy of platelet transfusion and analysis of influencing factors in 364 patients[J]. Acta Haematol,2023,146(3):214-219. [25] Cheng L H,Wang L,Wang S C,et al.The effect of physical cues on platelet storage lesion[J]. Hematology, 2025,30(1):2450573. [26] Laun L,Leunig A,Zhang F,et al. Splenic regulation of systemic platelet activation state[J]. Science,2026, 393(6817):eaec7230. [27] Karnicki K,Johnson C,St Cyr J,et al.Platelet storage solution improves the in vitro function of preserved platelet concentrate[J]. Vox Sang,2003,85(4):262-266. |